Invivyd appoints William Duke as CFO effective September 1, 2023

Invivyd, Inc.

William Duke (51) appointed CFO; previously CFO at Apexigen and Kaleido Biosciences.
Salary $475,000, initial target bonus 40% of salary, $20,000 signing bonus.
Received option to purchase 750,000 shares vesting over 4 years.
Duke led Apexigen through its sale to Pyxis Oncology and completed multiple financings.
CEO Hering cited Duke's experience as valuable for upcoming VYD222 clinical study and potential EUA submission.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

William Duke

Chief Financial Officer

IVVD · Invivyd, Inc.

Effective: 2023-09-01
Filed: September 5, 2023, 7:59 PM ET

On September 5, 2023, Invivyd, Inc. (the “Company”) announced the appointment of William Duke, age 51, as the Company’s Chief Financial Officer, effective as of September 1, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

William Duke was appointed as Chief Financial Officer at Invivyd, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On September 5, 2023, Invivyd, Inc. (the “Company”) announced the appointment of William Duke, age 51, as the Company’s Chief Financial Officer, effective as of September 1, 2023

View on SEC.gov

Invivyd, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-228074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.